More than 90% of children born with the rare bone marrow condition Shwachman-Diamond syndrome (SDS) survive beyond age 20. But fewer than 30% live beyond age 50. Long-term survival could improve if clinicians act on early signs of high risk, according to a study published, in The New England Journal of Medicine.
Multiple immunosuppressive therapies increase infection risks for cancer patients News-Medical
Rosandra Kaplan Highlights Pediatric Cancer Progress With Kids v Cancer at AACR Oncodaily
Svetlana Nikic Shares Key Precision Oncology Updates of the Week Oncodaily
Global Cancer Leaders Gather in Brussels to Mark 10 Years of World Cancer Research Day Oncodaily
When Hugo Aerts, PhD, started asking colleagues whether the thymus could play a role in determining which patients with cancer would respond to immunotherapy about 4 years ago, the responses were overwhelmingly dismissive. “It’s irrelevant,” they told him. “[The thymus is] important in kids. Afterwards, it doesn’t…
«Блокада не помогла»: состояние Лерчек ухудшилось — врачи ищут новые метастазы Vokrug.tv
Новый анализ нашел сигналы 17 типов рака в ходе тестирования RTVI.US
Chemotherapy faces a fundamental problem: The same drugs powerful enough to kill cancer cells can also damage healthy tissue. UC Irvine researchers are trying to change that equation by putting a safety lock on a highly potent cancer drug—a lock designed to be removed once the drug enters cancer cells with high levels…
Immune checkpoint inhibitors (ICIs) can promote antitumor responses but can also cause adverse effects that require treatment with immunosuppressive drugs. A new retrospective study by Mass General Brigham Cancer Institute investigators found that patients who received ICIs and multiple immunosuppressive therapies…
Most colon cancer deaths are caused by the spread of tumor cells beyond the colon, usually to the liver. In a new study, MIT biologists identified a cellular pathway necessary for colorectal cancer metastasis.
New trial aims to evaluate chemotherapy benefit for ER+/HER2- breast cancer patients News-Medical
Why Breast Cancer Clinical Trials Stop Early: Poor Accrual Remains the Leading Threat to Study Completion oncodaily.com